Oral MucoRice-CTB vaccine for safety and microbiota-dependent immunogenicity in humans: a phase 1 randomised trial-Reference-Cited by-同舟云学术

Oral MucoRice-CTB vaccine for safety and microbiota-dependent immunogenicity in humans: a phase 1 randomised trial

Published:2021-09 Issue:9 Volume:2 Page:e429-e440
ISSN:2666-5247
Container-title:The Lancet Microbe
language:en
Short-container-title:The Lancet Microbe

Author:

Yuki Yoshikazu,Nojima Masanori,Hosono Osamu,Tanaka Hirotoshi,Kimura Yasumasa,Satoh Takeshi,Imoto Seiya,Uematsu Satoshi,Kurokawa Shiho,Kashima Koji,Mejima Mio,Nakahashi-Ouchida Rika,Uchida Yohei,Marui Takanori,Yoshikawa Noritada,Nagamura Fumitaka,Fujihashi Kohtaro,Kiyono Hiroshi

Funder

Japan Agency for Medical Research and Development

Ministry of Education, Culture, Sports, Science and Technology

Science and Technology Research Partnership for Sustainable Development

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Microbiology (medical),Microbiology

Reference35 articles.

1. Updated global burden of cholera in endemic countries;Ali;PLoS Negl Trop Dis,2015

2. A review of vaccine research and development: human enteric infections;Girard;Vaccine,2006

3. Field trial of oral cholera vaccines in Bangladesh;Clemens;Lancet,1986